# XERIS BIOPHARMA HOLDINGS, INC. (XERS) · Edgar & Edgarette company card

> Xeris Biopharma Holdings (XERS) grew revenue 43.7% in FY2025 to $292 million, operating margin 8.5% against a -3.8% median for pharmaceutical preparations, equity 3.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1867096 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/XERS) · [JSON](https://www.pops4.com/boards/company/XERS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $292M |
| Revenue growth, 1 year | 43.7% |
| Revenue growth per year | 55.8% |
| Operating margin | 8.5% (prior year -16.6%) |
| Net margin | 0.2% |
| Operating cash flow | $29M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $111M |
| Long-term debt | $220M |
| Total assets | $384M |
| Total equity | $14M |
| Equity ÷ assets | 3.6% |
| Return on equity | 4.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -2.99 (distress zone)
- Piotroski F: 7 of 9 (solid)
- Health Harbor boat: Sound ship · one warning sign · revenue is hard to predict: its 80% range is ±30%
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $291.8M (FY2025), total debt $220.3M. Experience: revenue up 43.7% on the year, up 55.8% a year over 4 years; operating margin 8.5%, up from -16.6%. Soundness: equity 3.6% of assets, return on equity 4.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $295.9M and $553.5M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $252.6M to $652.6M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 8.5% against a -3.8% median; growth 43.7% against 13.7%.

Range logged 2026-11-01, receipt 453f84dec1e3bfab, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-11-02 ([filing](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000095/0001867096-26-000095-index.htm))

## Recent filings

- 8-K · filed 2026-11-02 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000095/0001867096-26-000095-index.htm)
- 8-K · filed 2026-10-14 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000091/0001867096-26-000091-index.htm)
- 8-K · filed 2026-09-09 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/0001867096-26-000077-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000065/0001867096-26-000065-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/0001867096-26-000063-index.htm)
- 8-K · filed 2026-07-17 · 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000055/0001867096-26-000055-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001867096.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1867096

## Cite

POPS4, Edgar & Edgarette: XERIS BIOPHARMA HOLDINGS, INC. (XERS) company card, from the company's own SEC filings, accessed 2026-11-03, https://www.pops4.com/boards/company/XERS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.